Processa Pharmaceuticals, Inc. Income Tax Examination, Penalties and Interest Expense
Processa Pharmaceuticals, Inc. (PCSA) reported Income Tax Examination, Penalties and Interest Expense of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Expense Statement
us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense · last filed 2025-03-20
- Processa Pharmaceuticals, Inc. income tax examination, penalties and interest expense for fiscal 2024 was $0.00.
- Processa Pharmaceuticals, Inc. income tax examination, penalties and interest expense for fiscal 2023 was $0.00.
- Processa Pharmaceuticals, Inc. income tax examination, penalties and interest expense for fiscal 2022 was $0.00.
- Processa Pharmaceuticals, Inc. income tax examination, penalties and interest expense for fiscal 2021 was $0.00.
| Period end | Income Tax Examination, Penalties and Interest Expense 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-20 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-20 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-29 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |